Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664149 | 0.73 | — | — | |
| SCHEMBL12162394 | 0.73 | — | — | |
| SCHEMBL1161908 | 0.73 | — | — | |
| SCHEMBL1161910 | 0.73 | — | — | |
| SCHEMBL29457985 | 0.71 | — | — | |
| SCHEMBL21119289 | 0.71 | — | — | |
| SCHEMBL20555240 | 0.71 | — | — | |
| SCHEMBL29359505 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL13368906 | 0.71 | — | — | |
| SCHEMBL31480135 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087650-A1 | VINYLOXY-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2026-04-30 | — | — | WO | disclosed |
| EP-4647127-A2 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4630424-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | Third Harmonic Bio, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025202889-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-10-02 | — | — | WO | disclosed |
| EP-3743070-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4461725-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2024-11-13 | — | — | EP | disclosed |
| WO-2021203010-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3572401-B1 | ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2021023617-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2021-02-11 | — | — | WO | disclosed |
| US-20210032196-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2021-02-04 | — | — | US | disclosed |
| EP-3743070-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | Fuijan Cosunter Pharmaceutical Co. Ltd. (CN) | 2020-09-29 | — | — | US | disclosed |
| WO-2019148044-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10266542-B2 | EZH2 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180265517-A1 | EZH2 Inhibitors | Mirati Therapeutics, Inc. | 2018-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | MARK1, MAP3K1, MAP3K20 | ALDH1A1 3134/4885 |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | ALDH1A1 2830/4885 |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | ALDH1A1 3310/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | ALDH1A1 3624/4885 |
| US-20210032196-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | ALDH1A1 633/4885 |
| US-20180265517-A1 | EZH2 Inhibitors | EZH2, BMI1, EED | ALDH1A1 1969/4885 |
| US-10266542-B2 | EZH2 inhibitors | EZH2, BMI1, EED | ALDH1A1 1969/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ALDH1A1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.